References:
Broglio, F., Guarracino, F., Benso, A., Gottero, C., Prodam, F., Granata, R., Avogadri, E., Muccioli, G., Deghenghi, R., & Ghigo, E. (2002). Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. European Journal of Pharmacology, 448(2–3), 193–200. https://pubmed.ncbi.nlm.nih.gov/12144941/
Locatelli, V., Rossoni, G., Schweiger, F., Torsello, A., De Gennaro Colonna, V., Bernareggi, M., Deghenghi, R., Müller, E. E., & Berti, F. (1999). Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology, 140(9), 4024–4031. https://pubmed.ncbi.nlm.nih.gov/10465272/
McDonald, H., Peart, J., Kurniawan, N., Galloway, G., Royce, S., Samuel, C. S., & Chen, C. (2018). Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiological Reports, 6(9), e13699. https://pubmed.ncbi.nlm.nih.gov/29756411/
Xu, X., Ding, F., Pang, J., Gao, X., Xu, R. K., Hao, W., Cao, J. M., & Chen, C. (2012). Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. American Journal of Physiology-Heart and Circulatory Physiology, 303(6), H703–H711. https://pubmed.ncbi.nlm.nih.gov/22842067/
Zhao, H., Liu, G., & Wang, T. (2014). The cardiovascular action of hexarelin. Acta Biochimica et Biophysica Sinica, 46(10), 902–907. https://pmc.ncbi.nlm.nih.gov/articles/PMC4178518/